Sponsored by
This is groundbreaking.. for pediatric (and probably adult) high grade gliomas including glioblastomas, anaplastic astrocytoma,s diffuse midline glioma and others, which have a BRAF mutation, treating with a BRAF inhibitor and possibly a MEK inhibitor resulted in most patients having a durable response. Survivals were better than those using the standard of care. This is early data and they are testing it in a clinical trial but it may be worth asking your doctor about if your path report mentions a BRAF mutation.